Research
Alpha Lipoic Acid
184 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Effectiveness of alpha lipoic acid supplementation on biochemical, clinical, and inflammatory parameters in patients with diabetic polyneuropathy: A systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the effects of alpha-lipoic acid (ALA) supplementation on biochemical, clinical, inflammatory, and functional parameters in patients with diabetic polyneuropathy. Of 23 outcomes analyzed, 19 showed significant improvements with ALA, particularly in symptoms like paresthesia, numbness, and burning sensations, especially at a dose of 600 mg/day. No significant changes were observed in HbA1c, nitric oxide levels, sural sensory nerve action potential, and peroneal motor nerve conduction velocity.
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.
Systematic review and meta-analysis of 11 RCTs involving 704 overweight or obese adults to evaluate the effects of alpha-lipoic acid (ALA) on intermediate disease markers. The analysis found no significant associations between ALA supplementation and changes in triglyceride, total cholesterol, HDL-C, LDL-C, HOMA-IR, and fasting blood glucose levels.
Effects of Photobiomodulation on Burning Mouth Syndrome: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis evaluating the effectiveness and safety of photobiomodulation or low-level laser therapy on burning mouth syndrome compared to placebo, clonazepam, and alpha-lipoic acid. Pain was less common, and quality of life was better with laser use compared to placebo and clonazepam, though the certainty of evidence was low.
Efficacy of Alpha Lipoic Acid Supplementation in Sperm Parameters: A Systematic Review and Meta-Analysis of Randomized Trials.
Systematic review and meta-analysis of five randomized trials with 250 patients evaluating alpha lipoic acid (ALA) supplementation on sperm parameters in infertile males. ALA was associated with improved sperm morphology and motility but did not significantly affect pregnancy rates or other sperm parameters.
Effects of alpha-lipoic acid supplementation on cardiometabolic risk factors: A systematic review and dose-response meta-analysis.
This systematic review and meta-analysis evaluated the effects of alpha-lipoic acid (ALA) supplementation on cardiometabolic syndrome risk factors. The analysis of 63 RCTs showed that ALA supplementation significantly decreased insulin resistance, waist circumference, BMI, fat mass, body weight, fasting blood glucose, total cholesterol, hemoglobin A1, triglycerides, and fasting insulin. No substantial effects were found on LDL cholesterol, blood pressure, and HDL cholesterol.
Efficacy of different therapeutic options for pain relief and treatment of burning mouth syndrome: a systematic review.
Systematic review of RCTs evaluating treatments for Burning Mouth Syndrome (BMS), including alpha-lipoic acid, topical clonazepam, and low-level laser therapy (LLLT). These interventions showed significant symptom improvement with few mild adverse effects, but further high-quality trials are needed.
Disease-modifying therapies for diabetic peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of nine RCTs comparing triple-combination therapy of alpha-lipoic acid, epalrestat, and mecobalamin to monotherapy or dual therapy for diabetic peripheral neuropathy. The triple-combination therapy showed better therapeutic outcomes and significant improvements in nerve conduction velocities and vibration perception thresholds.
Alpha-lipoic acid for diabetic peripheral neuropathy.
Systematic review of RCTs assessing alpha-lipoic acid (ALA) for diabetic peripheral neuropathy. Analysis of three trials with 816 participants found ALA probably has little or no effect on neuropathy symptoms or impairment at six months, with moderate-certainty evidence. Studies were at high risk of attrition bias.
Alpha Lipoic Acid Supplementation and Iron Homeostasis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
This systematic review and meta-analysis evaluated the effect of alpha lipoic acid (ALA) supplementation on iron metabolism parameters. The analysis included 10 studies with 529 participants and found no statistically significant effects of ALA on ferritin, serum iron, hemoglobin, and total iron binding capacity. However, subgroup analysis showed ALA significantly increased hemoglobin in patients with hematological disorders and in studies longer than 8 weeks.
The Chemoprotective Potentials of Alpha-lipoic Acid against Cisplatin-induced Ototoxicity: A Systematic Review.
Systematic review of studies examining the protective effects of alpha-lipoic acid against cisplatin-induced ototoxicity. Alpha-lipoic acid co-administration was found to protect auditory cells, improve auditory brainstem response and distortion product otoacoustic emission, and ameliorate biochemical and histological changes induced by cisplatin.
Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis.
Systematic review and network meta-analysis of 11 studies evaluating alpha lipoic acid (ALA) and gamma linolenic acid (GLA) for diabetic peripheral neuropathy. ALA and GLA significantly improved Total Symptom Score compared to placebo, with GLA having the highest probability of being the best for improving symptoms. Most adverse events were gastrointestinal disturbances, with no tolerability differences between ALA and control.
The efficacy of combining adjuvants with non-surgical periodontal therapy in individuals with type 2 diabetes: A Bayesian network meta-analysis.
Bayesian network meta-analysis of RCTs assessing adjuvant periodontal treatment effects on periodontal and HbA1c outcomes in adults with type 2 diabetes. Alpha lipoic acid combined with sub-gingival debridement showed significant improvements in HbA1c levels and periodontal probing depth reductions.
Comparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials.
Systematic review and network meta-analysis of randomized controlled trials evaluating the efficacy and safety of Chinese patent medicines (CPMs) as adjunctive therapy with mecobalamin or alpha-lipoic acid for diabetic peripheral neuropathy. The study confirms the efficacy and safety of 37 CPMs combined with these substances, though recommendations should be adopted with caution due to potential bias and low certainty of evidence.
Effects of Alpha-Lipoic Acid Supplementation on Weight Loss, Inflammatory, Lipid, and Hematological Levels in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of randomized controlled trials evaluating alpha-lipoic acid supplementation in patients with chronic kidney disease. ALA significantly reduced high-sensitivity C-reactive protein, total cholesterol, and low-density lipoprotein cholesterol levels, but had no significant effect on weight, body mass index, hemoglobin, iron, IL-6, malondialdehyde, high-density lipoprotein cholesterol, or triglycerides.
Can Lifestyle and Behavioral Interventions Improve Weight Management in Individuals With Spinal Cord Injury? A Systematic Review and Meta-analysis.
Systematic review and meta-analysis of 61 studies, including 5 RCTs, evaluating lifestyle and behavioral interventions on body composition in individuals with spinal cord injury. Exercise, alone or with FES, supplements, or educational sessions, was the most studied intervention. Exercise regimens showed a decrease in BMI and waist circumference, while α-lipoic acid supplementation was identified as a potentially beneficial intervention.
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Meta-analysis and systematic review of 10 RCTs with 1242 patients evaluating oral alpha-lipoic acid (ALA) for diabetic sensorimotor peripheral neuropathy (DSPN). ALA improved total symptoms' score (TSS) and global satisfaction score, showing a dose-dependent response. However, ALA did not produce favorable results for VAS, VPT, NIS-LL, and NCS results.
The effect of alpha-lipoic acid on sperm functions in rodent models for male infertility: A systematic review.
Systematic review of 23 studies assessing the protective effect of alpha-lipoic acid (ALA) on sperm functions in rodent models of male infertility. ALA was found to restore sperm parameters, reduce sperm DNA damage, exhibit antioxidant and anti-inflammatory effects, modulate androgenesis, and restore testicular architecture and reproductive performance.
Effectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type I and type II diabetes mellitus: A systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the effectiveness of alpha-lipoic acid (ALA) in improving functional and symptomatic outcomes in patients with type I and type II diabetes mellitus. The findings suggest that ALA does not exhibit significant differences in terms of pain reduction and functional scales compared to placebo.
The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials
This systematic review and meta-analysis examined the effect of alpha-lipoic acid (ALA) on cardiometabolic risk factors and hormonal parameters in women with polycystic ovary syndrome (PCOS). Seven RCTs were included, showing significant reductions in fasting blood sugar and insulin resistance with ALA supplementation, suggesting it as an effective complementary therapy for managing PCOS.
Effect of Alpha-Lipoic Acid in the Treatment of Diabetic Neuropathy: A Systematic Review
Systematic review evaluating the effect of alpha-lipoic acid in the treatment of diabetic neuropathy. Eight studies with 1,500 diabetic patients were included. Findings were inconsistent, with 37.5% of trials observing significant symptom improvements and 62.5% not observing notable results. Alpha-lipoic acid was found to be safe and tolerable, with no adverse effects reported.
Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials
Systematic review and dose-response meta-analysis of 16 trials with 1035 patients examining oral alpha-lipoic acid supplementation in type 2 diabetes management. Each 500 mg/day increase in ALA significantly reduced HbA1c, body weight, CRP, FPG, and TG, but effects were not clinically important.
Effects of Alpha-lipoic Acid Supplementation on Human Diabetic Nephropathy: A Systematic Review and Meta-analysis.
Systematic review and meta-analysis examining the effects of alpha-lipoic acid (ALA) supplementation on biological indices indicative of diabetic nephropathy in humans. ALA supplementation decreased urine albumin excretion rate and urine albumin to creatinine ratio, but did not improve overall biological indices reflecting diabetic nephropathy. The evidence is limited and should be considered with caution.
Treatments for Burning Mouth Syndrome: A Network Meta-analysis.
This systematic review and network meta-analysis evaluated the effectiveness of treatments for pain relief in burning mouth syndrome (BMS). It included 44 trials, with 24 in the NMA, assessing interventions like photobiomodulation therapy, alpha-lipoic acid, phytotherapics, and anxiolytics/antidepressants. Clonazepam showed probable pain reduction compared to placebo, while other treatments had low certainty due to imprecision and indirectness.
α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders: An Mechanistic Perspective.
Systematic review of alpha-lipoic acid's potential as a therapeutic agent for neurodegenerative disorders. The review highlights its neuroprotective effects through inhibition of reactive oxygen species, modulation of protein levels, and promotion of neurotransmitter and antioxidant levels.
Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials.
Network meta-analysis of 15 RCTs with 3073 participants assessing efficacy and safety of medications for severe COVID-19. No significant decrease in all-cause mortality was found for α-lipoic acid and other treatments compared to standard care. Methylprednisolone showed a significant decrease in mortality compared to placebo.
Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Systematic review and meta-analysis of 11 studies with 1294 participants evaluating the effects of α-lipoic acid combined with valsartan on renal function in patients with diabetic nephropathy. The combination significantly reduced urinary albumin excretion rate and oxidative stress, increased antioxidant capacity, and alleviated renal function damage compared to monotherapy.
An updated systematic review and dose-response meta-analysis of the randomized controlled trials on the effects of alpha-lipoic acid supplementation on inflammatory biomarkers.
This systematic review and dose-response meta-analysis of 20 randomized controlled trials evaluated the effects of alpha-lipoic acid (ALA) supplementation on inflammatory markers in adults. ALA supplementation significantly reduced CRP, IL-6, and TNF-α concentrations, indicating improved inflammatory markers without evidence of non-linear association to dose or duration.
Alpha-lipoic acid supplementation affects serum lipids in a dose and duration-dependent manner in different health status.
This systematic review and dose-response meta-analysis evaluated the effect of alpha-lipoic acid (ALA) supplementation on lipid profiles, including total cholesterol, LDL, HDL, and triglycerides. The analysis included 12 studies with 548 participants, showing significant reductions in total cholesterol, LDL, and triglycerides, with a non-significant increase in HDL. The beneficial effects on LDL and triglycerides were found to be duration-dependent.
Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial.
This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and efficacy of alpha-lipoic acid (ALA) supplementation in reducing idiopathic pain in 210 normoglycemic adults. The study found that ALA significantly reduced pain scores on the numerical rating scale (NRS) and visual analogue scale (VAS) without affecting glycemia or causing adverse effects.
The efficiency of alpha-lipoic acid in the treatment of burning mouth syndrome: a systematic review.
Systematic review of randomized controlled trials evaluating the use of alpha-lipoic acid (ALA) for treating burning mouth syndrome (BMS). Some studies showed positive results, but findings are ambiguous and require further investigation.
A systematic review of treatment for patients with burning mouth syndrome.
Systematic review of treatments for burning mouth syndrome, including anticonvulsants, antidepressants, phytomedicine, alpha lipoic acid supplements, and other therapies. Phytomedicines showed short-term pain score reduction, while alpha lipoic acid had low pooled effect but increased positive effects in long-term assessment.
The radioprotective effects of alpha-lipoic acid on radiotherapy-induced toxicities: A systematic review.
Systematic review of 29 articles examining the role of alpha-lipoic acid in preventing or reducing radiation-induced toxicities in healthy cells/tissues. Alpha-lipoic acid was found to alleviate toxicities through anti-oxidant, anti-apoptosis, and anti-inflammatory mechanisms.
An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults.
This systematic review and dose-response meta-analysis evaluated the effects of α-lipoic acid (ALA) supplementation on glycemic markers in adults. The analysis included 28 studies with a total of 1,016 participants, showing that ALA supplementation significantly reduced insulin and HOMA-IR, with no change in glucose or HbA1C. The effect on insulin was duration-dependent.
Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study.
This randomized, double-blinded, placebo-controlled study assessed the efficacy of oral 600mg alpha-lipoic acid (ALA) twice daily over 6 months in 200 patients with diabetic peripheral neuropathy (DPN). ALA-treated patients showed significantly better results in neurological symptom score, neurological disability score, visual analog scale for pain, and vibration perception threshold compared to placebo. Mild nausea was reported in 6 patients, but no treatment discontinuations occurred.
The role of alpha lipoic acid in female and male infertility: a systematic review.
Systematic review examining the role of alpha lipoic acid (ALA) in female and male infertility. The review found positive effects of ALA on oocyte maturation, fertilization, embryo development, and reproductive outcomes. ALA also reduced pelvic pain in endometriosis, regularized menstrual flow, and improved sperm quality.
Alpha-lipoic acid effect on leptin and adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of randomized controlled trials assessing the effect of alpha-lipoic acid (ALA) supplementation on serum leptin and adiponectin levels. The analysis found a significant decrease in serum leptin concentrations and a significant increase in adiponectin levels, particularly in studies lasting more than 8 weeks.
Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials.
Systematic review and dose-response meta-analysis of randomized placebo-controlled trials evaluating alpha-lipoic acid (ALA) supplementation on obesity measurements. ALA treatment significantly reduced weight and BMI, with the duration of treatment affecting waist circumference reduction, particularly significant among women.
Role of alpha-lipoic acid in vascular function: A systematic review of human intervention studies.
Systematic review of human intervention studies evaluating the effect of alpha-lipoic acid (ALA) on vascular function. Of 11 trials evaluating endothelial function, 10 reported significant improvement, while none of the trials on endothelium-independent vasodilation showed favorable impact. ALA appears to improve endothelial function by increasing nitric oxide bioavailability and decreasing oxidative stress and inflammation.
Pharmacological and non-pharmacological management of burning mouth syndrome: A systematic review.
Systematic review discussing the management of burning mouth syndrome (BMS), including pharmacological and non-pharmacological interventions. Alpha-lipoic acid (ALA) is mentioned as one of the interventions with some evidence of efficacy, though large-scale clinical trials are needed.
Effects of alpha-lipoic acid supplementation on C-reactive protein level: A systematic review and meta-analysis of randomized controlled clinical trials.
Meta-analysis of 11 randomized controlled trials assessing the effects of alpha-lipoic acid supplementation on C-reactive protein (CRP) levels. The analysis showed a significant reduction in CRP levels, particularly in non-diabetic patients and when baseline CRP was greater than 3 mg/l or trial duration exceeded 8 weeks.
Effect of alpha-lipoic acid supplementation on lipid profile: A systematic review and meta-analysis of controlled clinical trials.
This systematic review and meta-analysis summarized clinical trials examining the effects of alpha-lipoic acid (ALA) supplementation on lipid profiles in adults. The analysis included 11 trials with 452 adults and found that ALA supplementation significantly decreased serum concentrations of triacylglycerol, total cholesterol, and low-density lipoprotein, but did not affect high-density lipoprotein levels.
Effects of alpha lipoic acid and its derivative "andrographolid-lipoic acid-1" on ulcerative colitis: A systematic review with meta-analysis of animal studies.
Systematic review and meta-analysis of 22 animal studies (70 rats and 162 mice) on the effects of alpha lipoic acid (ALA) and its derivative andrographolid-lipoic acid-1 (AL-1) in ulcerative colitis. ALA and AL-1 significantly reduced tumor necrosis factor-α levels and myeloperoxidase activity, although meta-analysis results were not statistically significant. Most studies reported significant positive effects on inflammatory and oxidative parameters.
Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis.
Meta-analysis evaluating the efficacy of lipoic acid, prostaglandin E1, and methylcobalamin (L+P+M) for diabetic peripheral neuropathy compared to prostaglandin E1 plus methylcobalamin (P+M). L+P+M therapy showed significantly better clinical efficacy and improved nerve conduction velocities than P+M therapy.
Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy.
Systematic review and meta-analysis of pharmacologic therapies for painful diabetic peripheral neuropathy (pDPN) including 58 studies with 11,883 patients. Alpha-lipoic acid showed a relative risk of 50% pain reduction, indicating potential efficacy among various treatments analyzed.
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
Meta-analysis of four randomized, double-masked, placebo-controlled trials involving 1258 diabetic patients with symptomatic polyneuropathy. Treatment with 600 mg/day intravenous alpha-lipoic acid over 3 weeks significantly improved neuropathic symptoms and deficits compared to placebo, with a 24.1% improvement in Total Symptom Score and a 16.0% improvement in Neuropathy Impairment Score of the lower limbs.
Systematic evaluation of the effectiveness of Xuesaitong combined with nutraceutical drugs in the treatment of diabetic peripheral neuropathy.
A 12-week RCT with 140 DPN patients comparing Xuesaitong combined with nutraceuticals to nutraceuticals alone. The combination therapy showed significantly greater improvements in nerve conduction velocities, pain intensity, neuropathy symptoms, inflammation, oxidative stress, and quality of life.
PREVENTION OF PACLITAXEL-INDUCED MOTOR NEUROPATHY OF FIBULAR AND TIBIAL NERVES WITH ALPHA-LIPOIC ACID AND IPIDACRIN HYDROCHLORIDE IN BREAST CANCER PATIENTS.
RCT investigating the use of alpha-lipoic acid (ALA) and ipidacrine hydrochloride (IPD) for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients. The study found that ALA and IPD improved the functional state of axons, with higher M-response rates in the treatment group after 6 cycles of chemotherapy.
Evaluating the efficacy and tolerability of the oral combination of alpha lipoic acid and vitamin B complex preparation in carpal tunnel syndrome: a single center, randomized, double-blind, placebo-controlled trial
RCT evaluating the efficacy and tolerability of an oral combination of alpha-lipoic acid and vitamin B complex in 70 patients with mild to moderate carpal tunnel syndrome. Significant improvement in VAS scores for pain control was observed in the treatment group, though other measures did not show statistically significant differences. The combination was well tolerated with minimal side effects.
Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.
This randomized controlled trial investigated the effects of alpha lipoic acid (ALA) as an adjuvant therapy on inflammation and cardiac function in 60 diabetic patients with ischemic cardiomyopathy. The ALA group showed significantly lower levels of inflammatory markers and improved cardiac function compared to the placebo group after three months.
The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial.
A 3-month randomized controlled trial evaluated the efficacy of 300 mg/day alpha-lipoic acid (ALA) as an adjuvant therapy for diabetic nephropathy in 50 participants with type 1 diabetes. ALA supplementation significantly reduced oxidative stress markers and urinary albumin excretion rate, suggesting a protective role against diabetes-induced oxidative damage.
A randomized, double-blind, placebo controlled study to evaluate the effect of alpha-lipoic acid on inhibition of ADP-and collagen-induced platelet aggregation ex vivo in diabetic neuropathy patients on gabapentin or pregabalin.
A randomized, double-blind, placebo-controlled study evaluated the effect of alpha-lipoic acid (ALA) on platelet aggregation and lipid profile in diabetic neuropathy patients on gabapentin or pregabalin. ALA significantly inhibited collagen-induced and ADP-induced platelet aggregation and reduced cholesterol levels over 12 weeks compared to placebo, demonstrating protective effects against diabetic peripheral neuropathy.
Effect analysis of tanshinone IIA sulfonate sodium combined with a-lipoic acid in patients with diabetes peripheral neuropathy.
RCT comparing the effects of tanshinone IIA sulfonate sodium combined with α-Lipoic acid versus tanshinone IIA sodium sulfonate alone in patients with diabetes peripheral neuropathy. The combination improved blood glucose and lipid levels, reduced oxidative stress, and enhanced nerve conduction function.
Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial.
RCT evaluating the effectiveness of a rehabilitation program combined with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferol in treating sciatica due to herniated discs in young patients. The Combo group showed statistically superior results for pain, disability, and quality of life compared to other groups.
Alpha-lipoic acid does not improve olfactory training results in olfactory loss due to COVID-19: a double-blind randomized trial.
This double-blind randomized controlled trial assessed the effect of alpha-lipoic acid as an adjuvant to olfactory training in 128 post-COVID-19 patients with persistent smell loss. After 12 weeks, both the intervention and placebo groups showed significant improvements in olfactory function, but no significant differences were found between the groups, indicating alpha-lipoic acid did not enhance the effects of olfactory training.
Evaluation of Safety and Efficacy of Add-on Alpha-Lipoic Acid on Migraine Prophylaxis in an Adolescent Population: A Randomized Controlled Trial.
RCT evaluating the safety and efficacy of add-on alpha-lipoic acid (ALA) for migraine prophylaxis in 60 adolescent migraineurs. The test group receiving ALA showed significant reductions in migraine frequency, severity, and PedMIDAS scores, along with improved serum thiol and reduced CGRP levels compared to the control group.
Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial.
This randomized, double-blind, controlled trial compared alpha-lipoic acid (ALA), pregabalin, and their combination for treating neuropathic pain in 55 participants with various neuropathies. The study found that pregabalin was superior to ALA in reducing mean pain intensity, but there was no added benefit from combining ALA with pregabalin.
Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain.
RCT using a 3-period crossover design to assess the efficacy of an alpha-lipoic acid (ALA)-pregabalin combination for fibromyalgia pain. The study found no significant differences in pain, mood, or sleep outcomes between the combination and monotherapies, suggesting no additive benefit of combining ALA with pregabalin.
Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid,L. and, Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.
RCT evaluating the effect of a nutraceutical combination (alpha lipoic acid, Vitis vinifera, Ginkgo biloba) on sexual performance in males with type 2 diabetes and erectile dysfunction. The combination, especially when used with Avanafil, improved the International Index of Erectile Function score and reduced fasting plasma glucose and insulin resistance.
EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES.
RCT involving 100 breast cancer patients undergoing polychemotherapy with paclitaxel. The study assessed the effectiveness of alpha-lipoic acid (ALA) combined with ipidacrine hydrochloride (IPD) in preventing paclitaxel-induced peripheral neuropathy. Results showed that the combination significantly improved electrophysiological parameters of sensory nerves, suggesting reduced severity of nerve damage.
The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines.
RCT of 92 women with episodic migraines evaluating 300mg/day alpha-lipoic acid supplementation versus placebo for 12 weeks. ALA significantly decreased lactate and VCAM-1 serum levels, and improved headache severity, frequency, and impact scores compared to placebo. No significant changes in NO levels or migraine duration.
Effects of the Topical Use of the Natural Antioxidant Alpha-Lipoic Acid on the Ocular Surface of Diabetic Patients with Dry Eye Symptoms.
RCT investigating the effects of eye-drops containing 0.1% alpha-lipoic acid (ALA) and 0.3% hydroxy-propyl-methylcellulose (HPMC) on the ocular surface of diabetic patients with dry eye symptoms. The ALA/HPMC group showed significant improvements in tear film break-up time, Ocular Surface Disease Index, and corneal staining compared to the HPMC-only group.
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
RCT of 64 breast cancer patients assessing alpha-lipoic acid (ALA) as an adjuvant therapy to counteract paclitaxel-induced neuropathy and doxorubicin-associated cardiotoxicity. ALA significantly improved neuropathy grading and reduced serum levels of BNP, TNF-alpha, MDA, and neurotensin compared to placebo.
Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study.
This multi-center RCT investigated the impact of alpha-lipoic acid (ALA) on inflammation, oxidative stress, anemia, and glycemic parameters in 60 diabetic patients on hemodialysis. The ALA group showed significant improvements in inflammation markers, glycemic control, anemia parameters, and cardiovascular risk compared to the control group.
The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy.
A randomized, single-blind, sham-controlled trial evaluated the efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an add-on therapy to alpha-lipoic acid in individuals with symmetric distal polyneuropathy. The study found that FREMS, in addition to standard therapy, significantly improved pain severity, quality of life, and clinical global improvement over 8 weeks.
Antioxidants Supplementation in Acute Amitriptyline Abuse for Pain.
RCT investigating the role of antioxidant supplementation in alleviating oxidative stress induced by acute amitriptyline intoxication. Subjects were divided into groups receiving placebo, routine standard treatment (RST), RST with vitamin C, RST with alpha lipoic acid (ALA), or RST with both vitamin C and ALA. Supplementation with ALA and vitamin C reduced oxidative stress more effectively than routine treatment alone.
Alpha lipoic acid with pulsed radiofrequency in treatment of chronic lumbosacral radicular pain: A prospective, randomized study.
Prospective randomized study evaluating the effect of adding alpha lipoic acid (ALA) to pulsed radiofrequency (PRF) for treating chronic lumbosacral radicular pain in 120 patients. Group treated with ALA showed significantly higher success rates and lower pain scores compared to PRF alone, with no major complications reported.
The efficacy of alpha-lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double-blind, placebo-controlled clinical trial.
RCT of 92 women with episodic migraine, comparing 300mg alpha-lipoic acid (ALA) to placebo twice daily for 3 months. ALA significantly decreased serum levels of MDA and CRP, and improved depression, anxiety, and stress scores compared to placebo.
Alpha-lipoic acid supplementation effects on serum values of some oxidative stress biomarkers in women with gestational diabetes.
RCT of 60 women with gestational diabetes comparing alpha-lipoic acid (ALA) supplementation to placebo for 8 weeks. ALA improved serum values of fasting blood sugar, total antioxidant capacity, oxidative stress index, total antioxidant gap, and catalase significantly.
Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.
Clinical trial investigating lipoic acid supplementation in patients with multiple sclerosis found high-grade proteinuria as an adverse event. Describes four biopsy-proven cases of NELL1-associated membranous nephropathy following lipoic acid supplementation, with remission after discontinuation and supportive therapy.
Randomized clinical trial of combined therapy with oral α-lipoic acid and NB-UVB for nonsegmental stable vitiligo.
RCT evaluating the efficacy and safety of oral alpha-lipoic acid (ALA) in combination with NB-UVB phototherapy for nonsegmental stable vitiligo. The study found no significant difference in repigmentation rates between the ALA and placebo groups over 6 months.
The synergic effects of alpha-lipoic acid supplementation and electrical isotonic contraction on anthropometric measurements and the serum levels of VEGF, NO, sirtuin-1, and PGC1-α in obese people undergoing a weight loss diet.
This randomized clinical trial investigated the effects of 1200 mg/day alpha-lipoic acid supplementation and Faradic electrical stimulation on anthropometric parameters and serum levels of VEGF, NO, Sirtuin-1, and PGC1-α in 100 obese adults undergoing a weight loss diet. The α-LA + Faradic group showed significant improvements in weight, BMI, body fat, and waist circumference compared to other groups, suggesting a synergistic effect.
Effects of probiotic and alpha-lipoic acid supplements, separately or in combination on the anthropometric indicators and maintenance of weight in overweight individuals.
RCT evaluating the effects of probiotic and alpha-lipoic acid (ALA) supplements on weight maintenance in overweight individuals. The probiotic + ALA group showed significant improvements in weight, waist circumference, and CRP levels compared to other groups, suggesting benefits in maintaining reduced weight and reducing inflammation.
A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations.
RCT of 81 overweight or obese adults evaluating the effects of 600 mg/day R-alpha-lipoic acid supplementation over 24 weeks. The study found significant BMI reduction, increased antioxidant enzyme synthesis, and reduced inflammation markers in the R-LA group compared to placebo.
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
RCT of 70 diabetic patients comparing 1200mg alpha lipoic acid to placebo over 8 weeks. ALA significantly decreased ox-LDL, total Lp-PLA2 mass, and apoB-associated Lp-PLA2, and increased the percent of HDL-Lp-PLA2, suggesting a potential reduction in CVD risk.
Effect of alpha-lipoic acid at the combination with mefenamic acid in girls with primary dysmenorrhea: randomized, double-blind, placebo-controlled clinical trial.
This randomized, double-blind, placebo-controlled clinical trial evaluated the effects of alpha-lipoic acid (ALA) and mefenamic acid, alone and in combination, on primary dysmenorrhea in female students. ALA at 600 mg was found to be more effective than mefenamic acid at 250 mg in reducing menstrual pain, and the combination of ALA and mefenamic acid showed significant pain relief.
Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: A Systematic Review and meta- analysis.
Systematic review and meta-analysis of 41 RCTs assessing the effect of Alpha-Lipoic Acid (ALA) on glycemic and inflammatory biomarkers. ALA significantly improved fasting blood sugar, HbA1c, TNF-alpha, IL-6, and CRP levels, but had no effect on insulin and HOMA-IR.
Effectiveness of an antioxidant preparation with N-acetyl cysteine, alpha lipoic acid and bromelain in the treatment of endometriosis-associated pelvic pain: LEAP study.
Multicenter, open-label clinical trial assessing the impact of an antioxidant preparation with N-acetyl cysteine, alpha lipoic acid, and bromelain on endometriosis-associated pelvic pain in 398 women. Significant improvement in pain was observed over 6 months, with reduced need for rescue analgesics.
The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials.
This systematic review and meta-analysis of 24 RCTs evaluated the effect of alpha-lipoic acid supplementation on glycemic control and lipid profiles in patients with metabolic diseases. ALA supplementation significantly decreased fasting glucose, insulin, insulin resistance, hemoglobin A1c, triglycerides, total cholesterol, and LDL-cholesterol, with no detrimental effect on HDL-cholesterol levels.
Treatment modalities for burning mouth syndrome: a systematic review.
Systematic review of treatment modalities for burning mouth syndrome (BMS), analyzing 29 papers. The review categorized treatments into antidepressants, alpha-lipoic acid, phytotherapeutic agents, analgesic and anti-inflammatory agents, and non-pharmacological therapies. Antidepressants and alpha-lipoic acid showed promising results, but more studies are needed for a definitive treatment strategy.
A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy.
Systematic review evaluating the efficacy, safety, and cost of alpha-lipoic acid (ALA) for diabetic polyneuropathy (DPN) treatment. The review includes 25 publications, with evidence supporting ALA's benefits at 600 mg per day for at least 3 weeks, showing minimal side effects. ALA is effective in treating DPN and may aid in weight management and insulin sensitivity.
Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review.
Systematic review assessing non-pharmacologic interventions for diabetic peripheral neuropathy symptoms. Alpha-lipoic acid was more effective than placebo for pain with moderate strength of evidence. Spinal cord stimulation was also effective but had serious complications. Most studies were short-term with quality deficits.
Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review.
Systematic review of 32 articles on alpha-lipoic acid (ALA) for psychiatric and neurological disorders. ALA showed improvement in schizophrenia symptoms and prevention of Alzheimer's disease progression. Preliminary results for other conditions like stroke, encephalopathy, and multiple sclerosis suggest potential benefits.
Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.
Meta-analysis of 10 randomized, double-blind, placebo-controlled studies on alpha-lipoic acid (ALA) for weight loss. ALA treatment resulted in a statistically significant greater mean weight loss of 1.27 kg and a mean BMI difference of -0.43 kg/m² compared to placebo. Study duration affected BMI change, but not weight change.
Systematic review of treatments for diabetic peripheral neuropathy.
Systematic review of treatments for diabetic peripheral neuropathy, including 27 trials on various treatments. Meta-analysis showed significant symptom score reduction with 600 mg i.v. and oral α-lipoic acid. Other treatments like opioids, botulinum toxin A, mexidol, reflexology, and Thai foot massage also showed beneficial results.
A systematic review of randomized trials for the treatment of burning mouth syndrome.
Systematic review of 24 RCTs for burning mouth syndrome treatment. Alpha-lipoic acid (ALA) and capsaicin showed significant improvements in pain as assessed by Visual Analogue Scales in some studies, but capsaicin led to dyspepsia. Clonazepam and psychotherapy also showed benefits in some studies. Conclusions are limited by short follow-up periods and high study variability.
Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?
Systematic review of studies evaluating alpha lipoic acid for neuropathic pain in diabetes. Found five RCTs and one meta-analysis, with significant improvement in Total Symptom Score in four RCTs. Intravenous administration of 600 mg daily showed clinically relevant pain reduction.
Management of burning mouth syndrome: systematic review and management recommendations.
Systematic review on the management of primary burning mouth syndrome (BMS), a chronic intraoral pain condition. The review highlights limited evidence for treatments, with emerging support for the antioxidant alpha lipoic acid, warranting further studies.
Alpha lipoic acid for dementia.
Systematic review assessing the role and clinical efficacy of alpha lipoic acid in the treatment of dementia. No randomized double-blind placebo-controlled trials were found, and no evidence exists to explore potential effects of ALA for dementia.
Effectiveness of Nonpharmacologic Treatments of Burning Mouth Syndrome: A Systematic Review.
Systematic review of nonpharmacologic treatments for burning mouth syndrome, including 27 RCTs and 6 open clinical trials. Alpha-lipoic acid, capsaicin, and acupuncture showed significant pain relief in several trials. Other interventions like tocopherol and catuama provided short-term relief. Most therapies were safe, but studies were highly biased and short-term.
Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
Systematic review and meta-analysis on the use of alpha lipoic acid for schizophrenia.
Examining oxidative stress as a mechanistic link between sleep irregularity and cardiovascular risk in young adults with chronic anxiety.
RCT examining oxidative stress as a link between sleep irregularity and cardiovascular risk in young adults with chronic anxiety. Antioxidant supplementation with alpha-lipoic acid, vitamin C, and vitamin E reduced oxidative stress and improved blood pressure regulation in the high TSTI group.
Alpha-Lipoic Acid Supplementation for Male Partner of Couples with Recurrent Pregnancy Loss: A Post hoc analysis in Clinical Trial.
Post hoc analysis of a clinical trial assessing the effect of alpha-lipoic acid (ALA) on sperm parameters in 37 couples with recurrent pregnancy loss. ALA supplementation reduced sperm DNA damage, lipid peroxidation, and improved sperm motility and chromatin compaction. The percentage of spontaneous pregnancy was higher in the ALA group compared to placebo.
Oxygen–Ozone Therapy Associated with Alpha Lipoic Acid Plus Palmitoylethanolamide and Myrrh versus Ozone Therapy in the Combined Treatment of Sciatic Pain Due to Herniated Discs: Observational Study on 318 Patients
Observational study comparing the efficacy of oxygen–ozone therapy alone versus combined treatment with alpha-lipoic acid, palmitoylethanolamide, and myrrh in 318 patients with sciatic pain due to herniated discs. The combined treatment group showed a slightly higher rate of complete pain remission compared to the ozone therapy alone group.
The effect of alpha lipoic acid supplementation on sperm functions in idiopathic asthenozoospermic patients: a case-controlled study
Case-controlled study assessing the efficacy of alpha lipoic acid (ALA) supplementation in 80 primary infertile males with idiopathic asthenozoospermia. ALA supplementation improved total motility, progressive motility, sperm vitality, semen volume, and sperm concentration, while decreasing abnormal morphology.
EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE.
RCT evaluating the efficacy of alpha-lipoic acid combined with ipidacrine hydrochloride to prevent paclitaxel-induced peripheral neuropathy in breast cancer patients. The combination significantly reduced neuropathy severity compared to control, improving functional capacity and quality of life.
Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial
Pilot randomized double-blind placebo-controlled trial evaluating the effect of alpha lipoic acid (ALA) on psychopathological scores, neurotrophic factors, and oxidative stress in 20 patients with treatment-resistant schizophrenia. ALA supplementation improved SANS scores and decreased oxidative stress, showing potential as an adjunctive treatment.
Effects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in β-thalassemia major patients: A cross-over randomised controlled clinical trial.
Cross-over RCT of 26 β-thalassemia major patients assessing 600 mg/d alpha lipoic acid (ALA) vs placebo for 8 weeks. ALA significantly decreased serum ferritin, MDA, and MDA/LDL-C ratio, and increased HDL-C. No significant effects on other biomarkers.
Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention
Retrospective observational study evaluating the safety and efficacy of alpha lipoic acid at various dosages in 322 subjects over 4 years. Higher dosages (800 and 1200 mg/day) improved glycemic status and lipid profile, with reductions in FPG, TC, LDL-C, Tg, and Hs-CRP levels. Adverse events included nausea, vomiting, dizziness, rash, hypoglycemia, and hypotension, with no significant differences among dosage groups.
Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in β-Thalassemia Major Patients: A Clinical Trial Crossover Study
This randomized crossover clinical trial studied the effects of alpha-lipoic acid (ALA) supplementation on cardiovascular disease risk factors in 20 β-thalassemia major patients. ALA significantly reduced serum osteoprotegerin levels, suggesting it may help prevent CVD progression in these patients.
A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)
A randomized, single-blind, active-controlled trial evaluated the clinical efficacy and safety of α-Lipoic acid (ALA) in 17 critically ill COVID-19 patients. The study found that ALA use was associated with a lower increase in SOFA score and a lower 30-day all-cause mortality compared to placebo, although the statistical difference was borderline due to the small sample size.